Xentuzumab

DRUG4 trials

Sponsors

Boehringer Ingelheim, University of Oxford

Conditions

Breast NeoplasmsCarcinoma, Non-Small-Cell LungNeoplasmsProstate Cancer

Early Phase 1

IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy

CompletedNCT05110495

University of OxfordProstate Cancer

Start: 2021-12-17End: 2023-05-27Updated: 2025-02-17

Phase 1

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

CompletedNCT02191891

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2014-10-21End: 2018-04-18Updated: 2025-06-25

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

CompletedNCT03099174

Boehringer IngelheimBreast Neoplasms, Neoplasms

Start: 2017-05-04End: 2024-05-16Updated: 2025-06-24

Phase 2

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

CompletedNCT03659136

Boehringer IngelheimBreast Neoplasms

Start: 2018-11-28End: 2022-05-11Updated: 2025-02-24

Related Papers

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.

2023-06-1214 citations

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors

Cancer Science2021-12-064 citations

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors.

2021-07-106 citations

A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.

Journal of Clinical Oncology2021-05-201 citations

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

2021-01-1519 citations

Abstract 3055: Xentuzumab, a humanized IGF-1 and IGF-2 ligand co-neutralizing monoclonal antibody, shows efficacy in a human breast cancer model of bone metastasis

Cancer Research2020-08-15

Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts

Cancer Research2020-02-151 citations

XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.

Journal of Clinical Oncology2019-05-203 citations

Abstract OT3-06-02: A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy)

Cancer Research2018-02-151 citations